Ammax Bio., Inc

AmMax Bio. is a private clinical-stage biotech company focused on the development of innovative cancer therapeutics. It leverages its expertise in translational science and drug development to pursue first-in-class or best-in-class therapeutics with significant market opportunity. AmMax was founded in 2020 out of a partnership with Amgen wherein AmMax licensed an exclusive worldwide right to a monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R). As part of the transaction, Amgen took a minority ownership in the company. At the core of AmMax's pipeline are AMB-066 and AMB-104. AmMax is collaborating with MD Anderson to develop AMB-066, an mAb targeting CSF1R in Phase 2a for treating colorectal cancer minimal residual disease (CRC MRD). AMB-104 is a novel antibody-drug conjugate utilizing Synaffix's linker-payload platform and in development for treating acute myeloid leukemia (AML) and potentially solid tumors. AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc, which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization. With a seasoned management team and a robust pipeline, AmMax is poised to grow into a leading biotech company. For more on AmMax Bio and its pipeline, please visit the Company’s website at: